Literature DB >> 21855835

Clinical and procedural characteristics of acute hemodynamic responders undergoing triple-site ventricular pacing for advanced heart failure.

Hiro Yamasaki1, Yoshihiro Seo, Hiroshi Tada, Yukio Sekiguchi, Takanori Arimoto, Miyako Igarashi, Kenji Kuroki, Takeshi Machino, Kentaro Yoshida, Nobuyuki Murakoshi, Tomoko Ishizu, Kazutaka Aonuma.   

Abstract

The advantages of triple-site ventricular pacing (Tri-V) compared to conventional biventricular site pacing (Bi-V) have been reported. We sought to identify the predictors of acute hemodynamic Tri-V responders. Acute hemodynamic studies were performed in 32 patients with advanced heart failure during Tri-V implantation. After the right ventricular (RV) and left ventricular (LV) leads were implanted for a conventional Bi-V system, an additional pacing lead was implanted in the RV outflow tract for Tri-V. The LV peak +dP/dt and tau were measured during AAI, Bi-V, and Tri-V pacing. A Tri-V responder was defined as a patient whose percentage of increase in the peak +dP/dt during Tri-V was >10% compared to of that during Bi-V. The baseline clinical variables and RV outflow tract lead location were analyzed to identify the characteristics of the Tri-V responders. Of the 32 patients, 10 (31%) were classified as Tri-V responders. The LV end-diastolic volume was greater (246 ± 48 vs 173 ± 53 ml, p <0.01), and the RV outflow tract lead was implanted at a greater outflow tract portion (p <0.05) in the Tri-V responders. Multivariate analysis revealed that only the baseline LV end-diastolic volume (per 50-ml greater) predicted the Tri-V response (odds ratio 2.87, 95% confidence interval 1.03 to 8.00, p <0.05). The area under the receiver operating characteristic curve for the LV end-diastolic volume was 0.84 (p <0.01) and an LV end-diastolic volume of >212 ml had a sensitivity of 80% and specificity of 77% to distinguish Tri-V responders. In conclusion, Tri-V provides greater hemodynamic effect for patients with a larger LV end-diastolic volume owing to its resynchronization effects on the LV anterior wall.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21855835     DOI: 10.1016/j.amjcard.2011.06.048

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

Review 1.  Updates in Cardiac Resynchronization Therapy for Chronic Heart Failure: Review of Multisite Pacing.

Authors:  Antonios P Antoniadis; Ben Sieniewicz; Justin Gould; Bradley Porter; Jessica Webb; Simon Claridge; Jonathan M Behar; Christopher Aldo Rinaldi
Journal:  Curr Heart Fail Rep       Date:  2017-10

Review 2.  Left ventricular endocardial pacing and multisite pacing to improve CRT response.

Authors:  Sylvain Ploux; Zachary Whinnett; Pierre Bordachar
Journal:  J Cardiovasc Transl Res       Date:  2012-01-11       Impact factor: 4.132

Review 3.  Multisite Pacing for Cardiac Resynchronization Therapy: Promise and Pitfalls.

Authors:  Antonios P Antoniadis; Jonathan M Behar; Simon Claridge; Tom Jackson; Manav Sohal; Christopher Aldo Rinaldi
Journal:  Curr Cardiol Rep       Date:  2016-07       Impact factor: 2.931

4.  Multi-lead pacing for cardiac resynchronization therapy in heart failure: a meta-analysis of randomized controlled trials.

Authors:  Mark K Elliott; Vishal Mehta; Nadeev Wijesuriya; Baldeep S Sidhu; Justin Gould; Steven Niederer; Christopher A Rinaldi
Journal:  Eur Heart J Open       Date:  2022-02-26

5.  Hemodynamic effects of Purkinje potential pacing in the left ventricular endocardium in patients with advanced heart failure.

Authors:  Mamoru Hamaoka; Takanao Mine; Takeshi Kodani; Hideyuki Kishima; Masataka Mitsuno; Tohru Masuyama
Journal:  J Arrhythm       Date:  2015-07-17

6.  Comparison of triple-site ventricular pacing versus conventional cardiac resynchronization therapy in patients with systolic heart failure: A meta-analysis of randomized and observational studies.

Authors:  Baowei Zhang; Junfang Guo; Guohui Zhang
Journal:  J Arrhythm       Date:  2017-12-21
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.